Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party ; day:18 ; month:10 ; year:2024 ; pages:1
Bone marrow transplantation ; (18.10.2024), 1
- Urheber
-
Penack, Olaf
Peczynski, Christophe
Boreland, William
Lemaitre, Jessica
Reinhardt, H. Christian
Afanasyeva, Ksenia
Avenoso, Daniele
Holderried, Tobias A. W.
Kornblit, Brian Thomas
Gavriilaki, Eleni
Martinez, Carmen
Chiusolo, Patrizia
Mico, Maria Caterina
Daguenet, Elisabeth
Wichert, Stina
Ozdogu, Hakan
Piekarska, Agnieszka
Kinsella, Francesca
Basak, Grzegorz W.
Schoemans, Hélène
Könecke, Christian
Moiseev, Ivan
Peric, Zinaida
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41409-024-02435-8
- URN
-
urn:nbn:de:101:1-2501072106183.346634965769
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Penack, Olaf
- Peczynski, Christophe
- Boreland, William
- Lemaitre, Jessica
- Reinhardt, H. Christian
- Afanasyeva, Ksenia
- Avenoso, Daniele
- Holderried, Tobias A. W.
- Kornblit, Brian Thomas
- Gavriilaki, Eleni
- Martinez, Carmen
- Chiusolo, Patrizia
- Mico, Maria Caterina
- Daguenet, Elisabeth
- Wichert, Stina
- Ozdogu, Hakan
- Piekarska, Agnieszka
- Kinsella, Francesca
- Basak, Grzegorz W.
- Schoemans, Hélène
- Könecke, Christian
- Moiseev, Ivan
- Peric, Zinaida
- SpringerLink (Online service)
Ähnliche Objekte (12)
ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program
eCP
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program
eCP
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program
eCP
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study